A Novel Assay to Quantify Treatment Response in Cystic Fibrosis (CF)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by National Jewish Health.
Recruitment status was  Recruiting
Cystic Fibrosis Foundation Therapeutics
Information provided by (Responsible Party):
Milene Saavedra, National Jewish Health
ClinicalTrials.gov Identifier:
First received: June 20, 2012
Last updated: June 21, 2012
Last verified: June 2012

Inflammation is present in the Cystic fibrosis (CF) airway from the time of infancy, and worsens with the onset of chronic infection. Therapies with proven benefit are associated with decreased airway inflammation. Thus, sensitive and reproducible biomarkers of airway inflammation have long been sought as a necessary component to improved clinical care and to facilitate therapeutic trials for CF. FEV1, the standard outcome measure in CF, is recognized as an insensitive outcome measure. the investigators have identified a panel of 10 genes which sensitively predict resolution of pulmonary inflammation, in response to therapy of an acute pulmonary exacerbation. With the goal of yielding a technically simple but unique CF biomarker assay, the investigators have tested whether proteins signified by these genes show large changes in expression following treatment of acute pulmonary exacerbations. Protein quantifications are among the most common measurements performed in clinical laboratories around the world. Based on preliminary findings that changes in white blood cell proteins mirror changes seen in the genes, the investigators propose to identify top candidate proteins, from the investigators gene panel, which change in response to exacerbation therapy. Once identified, these proteins will be quantified directly with a new blood test which is inexpensive and simple to perform. The investigators propose to validate this blood test in a single site trial. If successful, this proposal will yield a biomarker assay that will be available to validate in a multi-site trial and provide unique insights into mechanisms that regulate white blood cell activation and recruitment in CF lung disease.

Cystic Fibrosis Pulmonary Exacerbations and Baseline

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Novel Assay to Quantify Treatment Response in CF

Resource links provided by NLM:

Further study details as provided by National Jewish Health:

Primary Outcome Measures:
  • Change in leukocyte associated protein expression by flow cytometry and by leukocyte specific ELISA in response to acute exacerbation therapy [ Time Frame: 10-21 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in FEV1 in response to acute exacerbation therapy [ Time Frame: 10-21 days ] [ Designated as safety issue: No ]
  • Change in sputum IL-8 and neutrophil elastase in response to acute exacerbation therapy [ Time Frame: 10-21 days ] [ Designated as safety issue: No ]
  • Change in bacterial density in response to exacerbation therapy [ Time Frame: 10-21 days ] [ Designated as safety issue: No ]
  • Change in CRP in response to acute exacerbation therapy [ Time Frame: 10-21 days ] [ Designated as safety issue: No ]
  • Time to next exacerbation [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: May 2011
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Adult CF patients > 18 years of age undergoing treatment for acute pulmonary exacerbation


Inclusion Criteria:

  1. Documented diagnosis of CF.
  2. Age 18 years old or greater.
  3. Presentation at the start of treatment for a pulmonary exacerbation of CF.
  4. Ability to perform reproducible Pulmonary Function Tests and produce sputum.
  5. Willingness to comply with study procedure and willingness to provide written consent.

Exclusion Criteria:

  1. Presence of a condition or abnormality that, in the opinion of the Principal Investigator (PI), would compromise the safety of the patient or the quality of the data.
  2. Use of systemic steroids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01626157

Contact: Milene Saavedra, MD 303-270-2517 saavedram@njhealth.org
Contact: Connie St Clair, RN 303-270-2517 stclairc@njhealth.org

United States, Colorado
National Jewish Health Recruiting
Denver, Colorado, United States, 80206
Contact: Connie St Clair, RN    303-270-2517    stclairc@njhealth.org   
Contact: Marion Jones, RN    303-398-1265    jonesm@njhealth.org   
Principal Investigator: Milene Saavedra, MD         
Sub-Investigator: Jerry Nick, MD         
Sponsors and Collaborators
Milene Saavedra
Cystic Fibrosis Foundation Therapeutics
Principal Investigator: Milene Saavedra, MD National Jewish Health
  More Information

No publications provided

Responsible Party: Milene Saavedra, Assistant Professor, National Jewish Health
ClinicalTrials.gov Identifier: NCT01626157     History of Changes
Other Study ID Numbers: SAAVED11A0
Study First Received: June 20, 2012
Last Updated: June 21, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Cystic Fibrosis
Pulmonary Fibrosis
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 26, 2015